Direct Oral Anticoagulants in Cancer Patients. Time for a Change in Paradigm

被引：18

作者：

Wojtukiewicz, Marek Z. ^{[1
,2
]}

Skalij, Piotr ^{[1
,2
]}

Tokajuk, Piotr ^{[1
,2
]}

Politynska, Barbara ^{[3
,4
]}

Wojtukiewicz, Anna M. ^{[3
]}

Tucker, Stephanie C. ^{[5
]}

Honn, Kenneth V. ^{[5
,6
,7
]}

机构：

[1] Med Univ Bialystok, Dept Oncol, 12 Ogrodowa St, PL-15027 Bialystok, Poland

[2] Comprehens Canc Ctr, Dept Clin Oncol, 12 OgrodowaSt, PL-15369 Bialystok, Poland

[3] Med Univ Bialystok, Dept Philosophy & Human Psychol, 37 Szpitalna St, PL-15295 Bialystok, Poland

[4] Univ Cambridge, Robinson Coll, Cambridge CB3 9AN, England

[5] Sch Med, Dept Pathol, Bioact Lipids Res Program, Detroit, MI 48202 USA

[6] Wayne State Univ, Dept Chem, Detroit, MI 48202 USA

[7] Karmanos Canc Inst, Dept Oncol, Detroit, MI 48202 USA

来源：

CANCERS | 2020年 / 12卷 / 05期

关键词：

thrombosis; cancer; treatment; prophylaxis; anticoagulants; DOAC; MOLECULAR-WEIGHT HEPARIN; RECURRENT VENOUS THROMBOEMBOLISM; PANCREATIC-CANCER; VEIN THROMBOSIS; ACTIVE CANCER; RIVAROXABAN; PREVENTION; WARFARIN; RISK; DABIGATRAN;

D O I：

10.3390/cancers12051144

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Thrombosis is a more common occurrence in cancer patients compared to the general population and is one of the main causes of death in these patients. Low molecular weight heparin (LMWH) has been the recognized standard treatment for more than a decade, both in cancer-related thrombosis and in its prevention. Direct oral anticoagulants (DOACs) are a new option for anticoagulation therapy. Recently published results of large randomized clinical trials have confirmed that DOAC may be a reasonable alternative to LMWH in cancer patients. The following review summarizes the current evidence on the safety and efficacy of DOAC in the treatment and prevention of cancer-related thrombosis. It also draws attention to the limitations of this group of drugs, knowledge of which will facilitate the selection of optimal therapy.

引用

页数：15

共 50 条

[1] Direct oral anticoagulants in cancer-associated venous thromboembolism: It is high time for a change of therapeutic paradigm
Domienik-Karlowicz, Justyna
Jaguszewski, Milosz
Kurzyna, Marcin
[J]. CARDIOLOGY JOURNAL, 2020, 27 (04) : 347 - 349
[2] Direct oral anticoagulants in patients with cancer
Bossaer, John B.
Covert, Kelly L.
[J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2019, 76 (14) : 1019 - 1027
[3] Direct Oral Anticoagulants in Patients with Cancer
Shah, Surbhi
Datta, Yvonne H.
Norby, Faye
Alonso, Alvaro
[J]. BLOOD, 2016, 128 (22)
[4] Direct Oral Anticoagulants in Cancer Patients
Suryanarayan, Deepa
Lee, Agnes Y. Y.
Wu, Cynthia
[J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2019, 45 (06): : 638 - 647
[5] Direct Oral Anticoagulants in Cancer Patients
Cosma, Edward
Prunty, Jeremy J.
[J]. US PHARMACIST, 2018,
[6] Direct Oral Anticoagulants for Thromboprophylaxis in Ambulatory Patients with Cancer
Agnelli, Giancarlo
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (08): : 781 - 783
[7] Direct oral anticoagulants for thromboprophylaxis in ambulatory patients with cancer
Wang, Yiwei
Wang, Maoyun
Ni, Yuenan
Liang, Zongan
[J]. HEMATOLOGY, 2020, 25 (01) : 63 - 70
[8] Infrequent transition to direct oral anticoagulants in patients with cancer
Nouhravesh, Nina
Sindet-Pedersen, Caroline
Hellfritzsch, Maja
Al-Alak, Ali Akil
Kuemler, Thomas
Grove, Erik L.
Lamberts, Morten
[J]. DANISH MEDICAL JOURNAL, 2024, 71 (02):
[9] Direct oral anticoagulants have similar rates of bleeding compared to traditional anticoagulants in compensated cirrhosis patients.
Intagliata, Nicolas
Henry, Zachary
Maitland, Hillary
Shah, Neeral L.
Argo, Curtis K.
Northup, Patrick
Caldwell, Stephen H.
[J]. HEPATOLOGY, 2015, 62 : 588A - 589A
[10] Use of direct oral anticoagulants in ICU patients. Part I - Applied pharmacology
Wahab, Abdul
Patnaik, Rupali
Gurjar, Mohan
[J]. ANAESTHESIOLOGY INTENSIVE THERAPY, 2021, 53 (05) : 429 - 439

← 1 2 3 4 5 →